NotableEligibility criteria expanded, about 17 wordsShow 4 more changesShow less
Trial completed
Primary completion date changed from estimate of Jun 1, 2026 to Jul 6, 2026
Secondary endpoints: details revised at 3 of 24 entries
Site details revised at 5 of 5 sites
NotableTrial status: Not Yet Recruiting to Recruiting
Start date changed from estimate of Aug 1, 2025 to Aug 25, 2025
Site details revised at 5 of 5 sites
v2
Study First Submitted
Notable: the plan changed
Endpoints
Primary
Percentage change (%) of body weight from baseline after subcutaneous administration of YN-011 for 22 weeks
Timeframe: 22 weeks
Secondary (24)
Proportion of subjects with body weight loss ≥ 5%, ≥ 10%, and ≥ 15% from baseline after subcutaneous
Absolute change from baseline in body weight (Kg) after subcutaneous administration for 22 weeks
Changes from baseline in BMI after subcutaneous administration for 22 weeks
Changes from baseline in waist to hip circumference ratio after subcutaneous administration for 22 weeks
Changes from baseline in waist to height ratio after subcutaneous administration of YN-011 for 22 weeks
Show 19 moreShow less
Changes from baseline in systolic and diastolic blood pressure after subcutaneous administration for 22 weeks
Changes from baseline in blood lipids (including TC, TG, LDL-C, and high-density lipoprotein cholesterol [HDL-C]) after subcutaneous administration for 22 weeks, percentage change from baseline, and ratio to baseline
Changes from baseline in glycated hemoglobin (HbA1c) after administration subcutaneous for 22 weeks
Changes from baseline in fasting plasma glucose(FPG) after subcutaneous administration of YN-011 for 22 weeks;
Changes from baseline in fasting insulin after subcutaneous administration of YN-011 for 22 weeks;
Changes from baseline in blood uric acid after subcutaneous administration for 22 weeks, percentage change from baseline, and ratio to baseline
Safety assessment will be conducted throught the study by Incidence of adverse events (AEs) and serious adverse events (SAEs);
Safety assessment will be conducted throught the study by Mental health status via Patient Health Questionnaire-9 (PHQ-9)
Safety assessment will be conducted throught the study by Mental health status via Columbia Suicide Severity Rating Scale (C-SSRS)
Maximum plasma concentration (Cmax) of YN-011 via subcutaneous administration through the study
Timepoint of maximum plasma concentration (Tmax) of YN-011 via subcutaneous administration
Area under the concentration-time curve from the time zero to last measurable concentration (AUC0-t) of YN-011 via subcutaneous administration
Elimination half-life (t1/2) of YN-011 via subcutaneous administration
Apparent clearance (CL/F) of YN-011 via subcutaneous administration
Apparent volume of distribution (Vz/F) of YN-011 via subcutaneous administration
Trough concentration (Ctrough) of YN-011 via subcutaneous administration
Incidence of anti-drug antibody (ADA) against YN-011 in serum before and after subcutaneous administration
Incidence of neutralizing antibody (NAb) against YN-011 in serum before and after subcutaneous administration
Changes from baseline in Dual Energy X-ray Absorptiometry [DEXA] data report (DEXA data inculding total fat mass, muscle mass, regional visceral fat mass and total lean body mass) after subcutaneous administration of YN-011
Arms and interventions
Efsubaglutide 20 mg Quaque Week (QW)Experimental
The drug is administered once weekly, starting with a titration dose of 1 mg. The dose is up-titrated every 2 weeks in the sequence of 1 mg → 5 mg → 10 mg → 20 mg, reaching the target dose of 20 mg, the total treatment last for 22weeks.
Efsubaglutide 40 mg QWExperimental
The drug is administered once weekly, starting with a titration dose of 1 mg. The dose is up-titrated every 2 weeks in the sequence of 1 mg → 5 mg → 10 mg → 20 → 40mg, reaching the target dose of 40 mg, the total treatment last for 22weeks.
Efsubaglutide Alfa 40 mg Q2WExperimental
The drug is administered once weekly, starting with a titration dose of 1 mg. The dose is up-titrated every 2 weeks in the sequence of 1 mg → 5 mg → 10 mg → 20 → 40mg,when reaching to target dose of 40 mg, administered the drug every 2weeks. the total treatment last for 22weeks.
Efsubaglutide Alfa 80 mg QWExperimental
The drug is administered once weekly, starting with a titration dose of 1 mg. The dose is up-titrated every 2 weeks in the sequence of 1 mg → 5 mg → 10 mg → 20 → 40mg→ 80mg, reaching the target dose of 80 mg, the total treatment last for 22weeks.
Efsubaglutide Alfa 80 mg Q4WExperimental
The drug is administered once weekly, starting with a titration dose of 1 mg. The dose is up-titrated every 2 weeks in the sequence of 1 mg → 5 mg → 10 mg → 20 → 40mg→ 80mg,when reaching to target dose of 80 mg, administered the drug every 4weeks. the total treatment last for 22weeks.